

Adding Zika Virus to the FDA Priority Review Voucher Program Act

[Public Law 114–146]

[This law has not been amended]

[Currency: This publication is a compilation of the text of Public Law 114-146. It was last amended by the public law listed in the As Amended Through note above and below at the bottom of each page of the pdf version and reflects current law through the date of the enactment of the public law listed at <https://www.govinfo.gov/app/collection/comps/>]

[Note: While this publication does not represent an official version of any Federal statute, substantial efforts have been made to ensure the accuracy of its contents. The official version of Federal law is found in the United States Statutes at Large and in the United States Code. The legal effect to be given to the Statutes at Large and the United States Code is established by statute (1 U.S.C. 112, 204).]

AN ACT To expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. [21 U.S.C. 301 note] SHORT TITLE.

This Act may be cited as the “Adding Zika Virus to the FDA Priority Review Voucher Program Act”.

SEC. 2. EXPANDING TROPICAL DISEASE PRODUCT PRIORITY REVIEW VOUCHER PROGRAM TO ENCOURAGE TREATMENTS FOR ZIKA VIRUS DISEASE.

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—

- (1) by redesignating subparagraph (R) as subparagraph (S);
- (2) in subparagraph (Q), by striking “Filoviruses” and inserting “Filovirus Diseases”; and
- (3) by inserting after subparagraph (Q) the following:
“(R) Zika Virus Disease.”.